PRQR ProQR Therapeutics: Nilai perusahaan marang volume dodolan

Risks for ProQR Therapeutics N.V. (PRQR) are linked to potential failures in rare pathology therapy trials and financial dependence on counterparties. Growth is driven by the success of the Axiomer platform and milestone payments from pharma behemoths. Monetization relies on fixed partner payments. The EV/Sales trend reflects the real-time valuation of the business, where 1889.35 expresses the latest level of the metric.
ProQR - rincian analitis lan metrik utama (PRQR)

For ProQR Therapeutics N.V. (PRQR), a leader in RNA editing, the historical EV/Sales level on the GURU.Markets platform reflects the market value of the business relative to its revenue. This metric excludes the impact of debt load, allowing for an assessment of the net asset value per unit of turnover. The calculation is based on the ratio of enterprise value to annual revenue. For the innovative Axiomer platform, this indicator identifies whether shares are overbought or undervalued. Investors should utilize this data to identify points of price imbalance.